EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rare Forms of Cardiac Amyloidosis: Diagnostic Clues and Phenotype in Apo AI and AIV Amyloidosis

Adam Ioannou iD, Aldostefano Porcari iD, Rishi K Patel iD, Yousuf Razvi iD, Giulio Sinigiani, Ana Martinez-Naharro, Lucia Venneri, James Moon iD, Muhammad U Rauf iD, Helen Lachmann, Ashutosh Wechelakar, Philip N Hawkins iD und 2 weitere

Circulation: Cardiovascular Imaging · 2023

DOI: 10.1161/circimaging.123.015259 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Cardiovascular Imaging, 2023. Verfasst von Adam Ioannou und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., A.P., R.K.P., Y.R., A.M.-N., L.V., M.U.R., H.L., A.W…. Hauptthemen laut MEDLINE: Dysphonia, Amyloid Neuropathies, Familial, Immunoglobulin Light-chain Amyloidosis, Heart Failure. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Apo AI amyloidosis (AApoAI) and Apo AIV amyloidosis (AApoAIV) are rare but increasingly recognized causes of cardiac amyloidosis (CA). We sought to define the cardiac phenotype in AApoAI and AApoAIV using multimodality imaging. METHODS: We identified all patients with AApoAI and AApoAIV assessed at our center between 2000 and 2021, and 2 cohorts of patients with immunoglobulin light-chain amyloidosis (AL) and transthyretin amyloidosis matched for age, sex, and cardiac involvement. RESULTS: Forty-five patients had AApoAI, 13 (29%) of whom had cardiac involvement, 32 (71%) renal involvement, 28 (62%) splenic involvement, 27 (60%) hepatic involvement, and 7 (16%) laryngeal involvement. AApoAI-CA commonly presented with heart failure (n=8, 62%) or dysphonia (n=7, 54%). The Arg173Pro variant universally caused cardiac and laryngeal involvement (n=7, 100%). AApoAI-CA was associated with right-sided involvement, with a thicker right ventricular free wall (8.6±1.9 versus 6.3±1.3 mm versus 7.7±1.2 mm, P =0.004), greater incidence of tricuspid stenosis (4 [31%] versus 0 [0%] versus 0 [0%], P =0.012) and tricuspid regurgitation (6 [46%] versus 1 [8%] versus 2 [15%], P =0.048) than AL-CA and transthyretin CA. Twenty-one patients had AApoAIV, and cardiac involvement was more common than in AApoAI (15 [71%] versus 13 [29%], P =0.001). AApoAIV-CA most commonly presented with heart failure (n=12, 80%), and a lower median estimated glomerular filtration rate than AL-CA and transthyretin CA (36 mL/[min·1.73 m²] versus 65 mL/[min·1.73 m²] versus 63 mL/[min·1.73 m²], P 30 months, respectively), and a lower risk of mortality than matched patients with AL-amyloidosis (AL versus AApoAI: hazard ratio, 4.54 [95% CI, 2.02–10.14]; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DysphoniaAmyloid Neuropathies, FamilialImmunoglobulin Light-chain AmyloidosisHeart FailureCardiomyopathiesHumansApolipoprotein A-IPrealbuminEchocardiography

Stichwörter der Autor:innen

amyloidosisapolipoproteinhereditaryphenotypeprognosistransthyretin-related

Substanzen

Apolipoprotein A-IPrealbumin

Autor:innen und Institutionen

  • National Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., A.P., R.K.P., Y.R., A.M.-N., L.V., M.U.R., H.L., A.W., P.N.H., J.D.G., M.F.).
  • Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, European Reference Network for Rare, Low Prevalence an…
  • Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Italy (G.S.).
  • St Bartholomew's Hospital, W Smithfield, London, United Kingdom (J.M.).

ORCID-Profile: Adam Ioannou, Aldostefano Porcari, Rishi K Patel, Yousuf Razvi, James Moon, Muhammad U Rauf, Philip N Hawkins, Julian D Gillmore, Marianna Fontana

Förderung

  • British Heart Foundation

Zitieren

APA

Ioannou, A., Porcari, A., Patel, R. K., Razvi, Y., Sinigiani, G., Martinez-Naharro, A., Venneri, L., Moon, J., Rauf, M. U., Lachmann, H., Wechelakar, A., Hawkins, P. N., Gillmore, J. D., & Fontana, M. (2023). Rare Forms of Cardiac Amyloidosis: Diagnostic Clues and Phenotype in Apo AI and AIV Amyloidosis. Circulation: Cardiovascular Imaging. https://doi.org/10.1161/circimaging.123.015259

Vancouver

Ioannou A, Porcari A, Patel RK, Razvi Y, Sinigiani G, Martinez-Naharro A, et al. Rare Forms of Cardiac Amyloidosis: Diagnostic Clues and Phenotype in Apo AI and AIV Amyloidosis. Circulation: Cardiovascular Imaging. 2023. doi:10.1161/circimaging.123.015259

BibTeX
@article{Ioannou2023,
  author = {Ioannou, Adam and Porcari, Aldostefano and Patel, Rishi K and Razvi, Yousuf and Sinigiani, Giulio and Martinez-Naharro, Ana and Venneri, Lucia and Moon, James and Rauf, Muhammad U and Lachmann, Helen and Wechelakar, Ashutosh and Hawkins, Philip N and Gillmore, Julian D and Fontana, Marianna},
  title = {Rare Forms of Cardiac Amyloidosis: Diagnostic Clues and Phenotype in Apo AI and AIV Amyloidosis},
  journal = {Circulation: Cardiovascular Imaging},
  year = {2023},
  doi = {10.1161/circimaging.123.015259}
}
Kostenlos starten →